offspring pressure management in pa...

offspring pressure management in patients with solitary coronary artery disease (CAD) has not been evaluated in large trials. The benefits of combined therapy with beta blocker and diuretics are well known, however the efficacy of other combination regimens is les established. The International Verapamil-Trandolapril subject of attention is a randomized trial that compares a non-dihydropyridine with a beta blocker to determine the amplitude to which these medications affect issues in older adults with CAD. The trial was designed to criterion these agents in combination with other antihypertensive drugs

Patients chronicleed in the international, multicenter, prospective, randomized open-blinded reflection were 50 years or older and had documented CAD with essential hypertension. Patients allocated to a calcium antagonist strategy (CAS) were given verapamil sustained-release (SR) while patients allocated to a noncalcium antagonist strategy (NCAS) were given atenolol. If relations pressure was not adequately controll patients in the CAS cluster could receive trandolapril, an angiotensin-converting enzyme inhibitor, in addition to the verapamil; the NCAS assign places to could receive hydro-chlorothiazide in addition to the atenolol. If progeny pressure was still too high, dosages were increased. Finally, each arrange could receive the other group's other medication (i.e., hydrochlorothiazide in the CAS form into groups and trandolapril in the NCAS group)

Patients were followed each six weeks for the first six month and then biannually. The primary result was all-cause death, nonfatal myocardial infarction, or nonfatal thump Secondary outcomes included time to most numerous serious event, cardiovascular death, angina, cardiovascular hospitalizations, line pressure control, cancer, Alzheimer's disease, Parkinson's disease, and gastrointestinal tract bleeding.

Of the 22576 eligible participants, 11267 were assigned to the CAS clump and 11,309 to the NCAS cluster with a mean follow-up of 27 years. Overall, as look forward toed calcium antagonist use was more of common occurrence in the CAS group, and beta-blocker use was more oft-repeated in the NCAS group. There was no difference in primary consequences in the CAS group compared with the NCAS collection Other outcomes also were similar and remained likewise with subgroup analysis. The merely difference was that patients with heart failure appeared to do somewhat better with the NCAS strategy.

In the two groups, a little more than brace thirds of participants achieved vital fluid pressure control by 24 month Of note, patients in the CAS cluster appeared to have a reduc risk of developing diabetes. Further investigation hinted a protective effect of trandolapril in the CAS assign places to only: a 2-mg dosage of trandolapril was associated with a hazard ratio of developing diabetes of 086 while a 4-mg dosage was associated with a hazard ratio of 077

The authors infer that a verapamil SR-based antihypertensive strategy is equivalent to a beta blocker-based strategy. In the couple groups, most participants required a combination of pair to three medications to achieve descendants pressure control. Patients with heart failure had better issues in the NCAS group. unfolding of diabetes appeared to be delayed in the CAS cluster with a nonsignificant trend toward exhibition of diabetes apparent in patients taking hydrochlorothiazide.

Pepine CJ et al., for the INVEST investigators. A calcium antagonist v a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril close attention (INVEST): a randomized controlled trial. JAMA December 3 2003;290:2805-16

COPYRIGHT 2004 American Academy of Family Physicians

COPYRIGHT 2004 Gale Group